Detailed Product Description
Detailed Product Description
|Product Name:||Raloxifene Hydrochloride||Synonym:||Keoxifene Hydrochloride , Keoxifene HCL|
|CAS:||82640-04-8||Appearance||light yellow powder|
Name:raloxifene hcl, Raloxifene hydrochloride
Appearance:light yellow powder
Evista (Raloxifene Hydrochloride) is an estrogen
agonist/antagonist, referred to as a selective estrogen receptor
modulator (SERM) and belongs to the benzothiophene class of
compounds. The biological actions of Raloxifene are largely
mediated through binding to estrogen receptors. This binding
results in activation of estrogenic pathways in some tissues
(Agonism) and and the blockade of estrogenic pathways in other
2. Why is this medication prescribed:
(1) Raloxifene is used to prevent and treat osteoporosis (condition
in which the bones become thin and weak and break easily) in women
who have undergone menopause (change of life; end of menstrual
periods). Raloxifene is also used to decrease the risk of
developing invasive breast cancer (breast cancer that has spread
outside of the milk ducts or lobules into the surrounding breast
tissue) in women who are at high risk of developing this type of
cancer or who have osteoporosis. Raloxifene cannot be used to treat
invasive breast cancer or to prevent invasive breast cancer from
coming back in women who have already had the condition.
(2) Raloxifene also cannot be used to decrease the risk of
developing non-invasive breast cancer. Raloxifene is in a class of
medications called selective estrogen receptor modulators (SERMs).
Raloxifene prevents and treats osteoporosis by mimicking the
effects of estrogen (a female hormone produced by the body) to
increase the density (thickness) of bone. Raloxifene decreases the
risk of developing invasive breast cancer by blocking the effects
of estrogen on breast tissue. This may stop the development of
tumors that need estrogen to grow.
3. Use and Dose:
Evista is specifically approved for the treatment and prevention of
osteoporosis in postmenopausal women, the reduction in risk of
invasive breast cancer in postmenopausal women with osteoporosis
and the reduction in risk of invasive breast cancer in
postmenopausal women at high risk of invasive breast cancer. Evista
is supplied as a 60 mg tablet designed for oral administration. The
recommended initial dose of the drug is one 60 mg tablet daily,
which may be administered any time of day without regard to meals.
Active Pharmaceutical Ingredients;Raloxifene;
Intracellular receptor;Aromatics;Intermediates &
Fine Chemicals;Pharmaceuticals;Sulfur &
DMSO: 28 mg/mL, soluble
CAS DataBase Reference
82640-04-8(CAS DataBase Reference)
A nonsteroidal, selective estrogen receptor
modulator (SERM). Antiosteoporotic.
1, High quality with competitive price:
1) Standard: Enterprise Standard
2) All Purity≥98%
3) We are manufacturer and can provide high quality products with
2, Fast and safe delivery
1) Parcel can be sent out within 24 hours after payment. Tracking
2) Secure and discreet shipment. Various transportation methods for
3) Customs pass rate ≥99%
4) We have our own agent/remailer/distributor who can help us ship
our products very fast and safe, and we have stock in there for
3, We have clients throughout the world.
1) Professional service and rich experience make customers feel at
ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting
customers's requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class
service gain the trust and praise from the customers.